文献速递心境障碍

磁惊厥治疗与右侧单侧超短脉冲电休克治疗抑郁症的验证性疗效与安全性试验(CREST-MST)

Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST-MST): a randomised, double-blind, non-inferiority trial in Canada and the USA.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

这项在加拿大和美国三个学术中心开展的多中心随机双盲平行组非劣效性试验,纳入239例重性抑郁障碍患者,比较磁惊厥治疗(MST)与右侧单侧超短脉冲电休克治疗(RUL-UB ECT)的疗效与认知安全性。

要点

  • MST因非严重不良事件退出治疗3例,RUL-UB ECT组12例。

核心结论

  • MST在实现抑郁症缓解方面相对RUL-UB ECT显示非劣效,且认知安全性更优。
  • MST的整体风险获益特征支持其作为MDD一线惊厥治疗考虑,尤其适用于拒绝RUL-UB ECT者。

研究设计与样本

  • 多中心随机双盲平行组非劣效性试验,在加拿大和美国三个学术中心开展。
  • 纳入18岁及以上重性抑郁障碍患者,治疗至缓解、脱落或最多21次治疗。
  • MST采用双线圈中线额部放置;主要结局为HAMD-24缓解和AMT自传体记忆恶化。
  • 非劣效界值为缓解率绝对差异15%;AMT恶化定义为25%下降(相当于一个标准差)。
  • 2018年6月26日至2024年3月1日入组292例,随机分配239例,3例治疗前退出。

主要发现

  • RUL-UB ECT组12例、MST组3例因非严重不良事件退出治疗。
  • 研究在达到计划样本量前结束入组。

关键数值与推荐

  • 非劣效界值为缓解率绝对差异15%。
  • AMT恶化定义为25%下降,对应一个标准差的表现下降。

临床怎么用

  • MST可作为MDD一线惊厥治疗考虑,尤其适用于拒绝RUL-UB ECT的患者。
  • 临床选择惊厥治疗时需权衡MST的非劣效疗效与更优认知安全性。

局限性

  • 研究在达到计划样本量前结束入组。
  • 有生活经验者未直接参与研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Magnetic seizure therapy (MST) is an innovative convulsive therapy that is clinically beneficial for patients with depression and has fewer cognitive adverse effects. This trial aimed to confirm the efficacy, tolerability, and cognitive safety of MST compared with right unilateral ultra-brief pulse-width (RUL-UB) electroconvulsive therapy (ECT). METHODS: This multisite randomised, double-blind, parallel-group, non-inferiority trial was conducted at three academic centres across Canada and the USA. Participants aged 18 years and older with major depressive disorder (MDD) received treatment until they achieved remission, dropped out, or up to 21 total treatments. MST was delivered using a twin coil in a midline frontal position. Remission of depression on the Hamilton Rating Scale for Depression-24 item and worsening of autobiographical memory on the Autobiographical Memory Test (AMT) were the coprimary outcomes. The non-inferiority margin was 15% absolute difference in remission rates and AMT worsening was defined as 25% reduction, corresponding to one standard deviation reduction in performance. People with lived experience were not directly involved; the study was informed by indirect feedback from previous trials and clinical discussions with people with depression who declined ECT. The trial is registered with ClinicalTrials.gov, NCT03191058. FINDINGS: Between June 26, 2018 and March 1, 2024, 292 participants were enrolled, of whom 239 were randomly assigned and three withdrew before treatment across study sites (RUL-UB ECT: mean age 45·5 years [SD 14·8, range 18-78], 80% White, 65 [55%] female, 54 [45%] male; MST: mean age 44·5 years [SD 13·8, range 18-75], 100 [85%] White, 70 [60%] female, 47 [40%] male). Enrolment concluded before reaching the intended sample size. The difference in remission rates was 5·3% in favour of RUL-UB ECT (27·8%) compared with MST (22·5%), establishing non-inferiority of MST (Z-test p=0·048 [95% CI -4·4 to 14·9]). More RUL-UB ECT participants had worsening autobiographical memory (17·3%) compared with MST participants (2·7%; p=0·0003). 12 participants in the RUL-UB ECT group and three participants in the MST group withdrew from treatment due to non-serious adverse events. INTERPRETATION: MST showed non-inferior efficacy relative to RUL-UB ECT in achieving remission of depression, and a more favourable cognitive safety profile. Collectively, the overall risk-benefit profile of MST supports its consideration as a first-line convulsive therapy in MDD, particularly in those who refuse RUL-UB ECT. FUNDING: National Institutes of Mental Health.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Blumberger DM, McClintock SM, Thorpe KE, et al. Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST-MST): a randomised, double-blind, non-inferiority trial in Canada and the USA. Lancet Psychiatry. 2026. PMID: 41997695. doi:10.1016/S2215-0366(26)00060-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。